ivacaftor

FDA Drug Profile — Kalydeco

ivacaftor is listed in the FDA National Drug Code directory with 18 NDC codes, marketed under brand name including Kalydeco. Available dosage forms: powder, granule, tablet, film coated.

Drug details

Generic Name
ivacaftor
Brand Names
Kalydeco
Application Number
NDA207925
Sponsor
Alivus Life Sciences Limited
NDC Codes
18
Dosage Forms
POWDER, GRANULE, TABLET, FILM COATED
Routes
ORAL
Active Ingredients
IVACAFTOR

Indications and Usage

1 INDICATIONS AND USAGE KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data. ( 12.1 , 14 ) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.